Rubicon lifts operating margin as revenue growth outpaces costs
Q1FY27 net profit rose +10.42% QoQ, while management flagged input-cost and outsourcing pressures alongside plans for capacity and product expansion.
Filed 14 Aug 2026, 16:54 IST · after market close · Rubicon Research Ltd (RUBICON)
Key takeaways
- Consolidated revenue rose +3.98% QoQ while expenses grew +2.53%, lifting operating margin by 1.06 percentage points.
- Consolidated net profit increased +10.42% QoQ to Rs 84.78 cr, helped by a -10.33% decline in interest costs despite a 1.00 percentage-point rise in the tax rate.
- Operating margin reached 24.16%, 0.81 percentage points above the 23.35% median for 71 Healthcare peers that had reported.
Price around the results
Revenue momentum translated into higher operating profit
Rubicon Research’s consolidated revenue grew +3.98% QoQ, faster than expenses at +2.53%, which raised operating profit by +8.78% to Rs 129.12 cr. Profit before tax increased +11.84% as interest costs fell -10.33%, although depreciation rose +23.39%. Other income more than doubled QoQ, but at 5.15% of pre-tax profit it was not the main source of earnings.
Margin improved, but input costs and outsourcing remain pressure points
Operating margin expanded by 1.06 percentage points to 24.16% because revenue growth outpaced expense growth. Management said key input costs rose sharply sequentially due to the geopolitical situation, while capacity constraints increased reliance on outsourced manufacturing and pressured gross margins. The company also said it gave up some lower-margin business, which led to a marginal sequential decline in US revenue.
Margin recovered from the Q3FY26 low
Operating margin has moved from 22.89% in Q2FY26 to 22.74% in Q3FY26, 23.10% in Q4FY26 and 24.16% in Q1FY27, indicating a recovery after the Q3 trough rather than a sustained decline. Net profit growth was slower than pre-tax profit growth because the tax rate increased by 1.00 percentage point to 23.19%. The margin was 0.81 percentage points above the 23.35% median among 71 Healthcare peers.
Management pairs expansion plans with near-term cost items
Management said Q2FY27 was tracking for sequential USD revenue growth and that it saw strong revenue visibility in the coming quarters. The company said it had acquired its first US manufacturing facility, InvaTech Pharma Solutions LLC, and was using specialty-product cash flows to build a branded platform.
Results were filed after market close; prior reactions were positive
The consolidated results were filed after market close, so there was no current-session market reaction to assess. After the previous three results, the stock rose each time, with moves of +16.46%, +7.21% and +9.09%; the median absolute move was 9.09%.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹534 cr | ₹514 cr | +3.98% |
| Other income | ₹6 cr | ₹3 cr | +117.62% |
| Expenses | ₹405 cr | ₹395 cr | +2.53% |
| Operating profit | ₹129 cr | ₹119 cr | +8.78% |
| Operating margin (%) | 24.16% | 23.10% | — |
| Interest | ₹9 cr | ₹10 cr | -10.33% |
| Depreciation | ₹15 cr | ₹12 cr | +23.39% |
| Profit before tax | ₹110 cr | ₹99 cr | +11.84% |
| Tax | ₹26 cr | ₹22 cr | +16.85% |
| Net profit | ₹85 cr | ₹77 cr | +10.42% |
| EPS (₹) | ₹5.13 | ₹4.66 | +10.09% |
Operating margin of 24.16% compares with a Healthcare sector median of 23.35% across 71 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company received two product approvals in Q1 FY27, and 88% of approved products were commercialised.
Guidance & outlook
- The company expects strong revenue visibility in the coming quarters.
- Q2 FY27 is tracking for sequential USD revenue growth.
- The company expects FY27 operating EBITDA margins to hold at least 23%.
- The company is on track to achieve INR 5,000 million or more of R&D spend over nine quarters.
Expansion
- Rubicon acquired its first US manufacturing facility, InvaTech Pharma Solutions LLC.
New initiatives
- The company is deploying specialty product cash flows to build a branded platform.
Competition
- Metoprolol Tartrate held 48.0% volume market share in FY26.
- Baclofen volume market share was 35.3% in FY25 and 33.9% in FY26, with a first-place market-share rank shown.
Problems & risks
- Operating cash flow was adversely affected by delays in receiving significant GST refunds.
- Key input costs increased sharply sequentially because of the prevailing geopolitical situation.
- Own manufacturing capacity constraints increased reliance on outsourced manufacturing and pressured gross margins.
- The company gave up some relatively lower-margin business, causing a marginal sequential drop in US revenues.
- Remaining FY27 quarters will include ESOP, Arinna, New Jersey and Pithampur pre-revenue costs affecting EBITDA margins.
What to watch
- Whether operating margin holds above 24.16% after the reported increase in input costs.
- Whether sequential revenue growth continues after the +3.98% increase in Q1FY27.
- How ESOP, Arinna, New Jersey and Pithampur costs affect the company’s stated 23% FY27 operating EBITDA margin floor.